Associated Papers
Urogenital Abnormalities in Adenosine Deaminase Deficiency.
Pajno R et al.
Journal of Clinical Immunology, 2020
Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Cicalese MP et al.
Blood, 2016
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
Candotti F et al.
Blood, 2012
Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy.
Sauer AV et al.
The Journal of Clinical Investigation, 2012
Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A et al.
The New England Journal of Medicine, 2009
Genotype is an important determinant of phenotype in adenosine deaminase deficiency.
Hershfield MS
Current Opinion in Immunology, 2003
Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy.
Otsu M et al.
Human Gene Therapy, 2002
Molecular basis for paradoxical carriers of adenosine deaminase (ADA) deficiency that show extremely low levels of ADA activity in peripheral blood cells without immunodeficiency.
Ariga T et al.
Journal of Immunology (baltimore, Md. : 1950), 2001
Select a paper to view details